Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
cmon…..get serious
JCPenney continues to move forward with its strategic reopening plan with nearly all stores now open nationwide
The q will drop within days...imagine the spike! Going to be a 10 bagger short time
zero debt!
B. Debt Securities, Including Promissory and Convertible Notes
Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities..
Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ?
Date of Note Issuance
Outstanding Balance ($)
Principal Amount at Issuance ($)
Interest Accrued ($)
Maturity Date
Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)
Name of Noteholder (entities must have individual with voting / investment control disclosed).
Reason for Issuance (e.g. Loan, Services, etc.)
https://backend.otcmarkets.com/otcapi/company/financial-report/249692/content
impressive indeed! we will see pennies here in short time....
https://twitter.com/RnwfMerger
Impressed with the team over at $RNWF for their tenacity and drive bringing the company current and eliminating the CE status with OTCmarkets. We know this is often a difficult process.
We can't wait to see what they have coming next!
bringing the company current and eliminating the CE status with OTCmarkets[color=red][/color]
going to pennies tomorrow
https://www.otcmarkets.com/stock/RNWF/overview
PINK CURRENT!
I agree ADVFN....this news is more than amazing…..
hey Bula….do better DD dude…..
Read up zino….
The company has already taken care upon that stupid fake news and they pr-ed several times since last week (three times) and the news is VERY VERY exciting!
Great management and great company
"From a commercialization perspective we are truly optimistic about the implications of the current results, which may require us to consider expanding our clinical trial programs," said Timothy Dixon, President, and CEO of the Company. "The IDO enzymatic pathway is not only extremely interesting from a medical perspective, but companies working on manipulating this pathway have previously entered Big Pharma deals with potential values in excess of $1 billion [3]. In contrast to other programs that utilize synthetic approaches, QuadraMune™, which is comprised of natural ingredients and is available as a nutraceutical, may possess numerous advantages for accelerated commercialization."
wow....just wow....amazing news folks!!!!
focus on the company indeed!
great post and i agree 100%...the buying was because of the great news pr's last week and than came that stupid fake news this weekend, but the company took immediate action with an new pr....GREAT management here and we are going to skyrocket!
we are at best! :)
Read better dude….
UC San Diego Medical Center will lead the first large-scale study in the United States of the effectiveness of QuadraMune™ in preventing COVID-19 in healthcare workers and first responders who volunteer to participate
that's right OC!
Read folks! : UC San Diego Medical Center will lead the first large-scale study in the United States of the effectiveness of QuadraMune™ in preventing COVID-19 in healthcare workers and first responders who volunteer to participate
San Diego– UC San Diego Medical Center will lead the first large-scale study in the United States of the effectiveness of QuadraMune™ in preventing COVID-19 in healthcare workers and first responders who volunteer to participate. The study of QuadraMune has begun in earnest after a collaborative effort by Dr. James Veltmeyer, Therapeutic Solutions International and several major California medical centers.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases using their proprietary drug formulation QuadraMune™
"This is going to be the first major, definitive study in healthcare workers and first responders of QuadraMune as a preventative medication," said the study's organizer, UC San Diego Health Centers Dr. Ehtisham Mahmud , a world-renowned interventional cardiologist and researcher who has pioneered multiple treatments for heart disease. "There has been a lot of talk about this drug, but only a small, non-blinded study so far . We are going to change that in San Diego and produce a scientific answer to the question: Does it work?"
Dr. James Veltmeyer , San Diego's leading physician and Chief Medical Officer of Therapeutic Solutions International will oversee the study with Dr. Ehtisham Mahmud.
"We at Therapeutic Solutions International are pleased to apply our work in the area of inflammation and immune stimulation, to attempt to add another arrow in our quiver against this invisible enemy," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In some ways, Coronavirus is like cancer…you want to increase activation of innate immunity and suppress inflammatory reactions simultaneously. We have been doing this research successfully using NanoStilbene™ in cancer, and now we are transposing our findings into the field of virology with QuadraMune.
"We are glad to see UC San Diego's lead on this volunteer study that could help protect medical workers and first responders across the country " remarked CEO Christopher Kane of UC San Diego Health Physician Group.
With all the exciting news we will see 5's tomorrow
Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™
San Diego Top Doctor James Veltmeyer Leads Efforts to Demonstrate Efficacy of Immune Boosting Formulation in High-Risk Population
NEWS PROVIDED BY
Therapeutics Solutions International, Inc.
Jun 08, 2020, 09:00 ET
OCEANSIDE, California, June 8, 2020/PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting formulation QuadraMune™.
The trial is anticipated to recruit 500 subjects at risk of SARS-CoV-2 infection, the type of coronavirus which causes COVID-19.
The new clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is expected to appear on the Federal Clinical Trial registry this week.
Last week the Company announced data from a preliminary clinical trial in which four groups of eight volunteers were treated with placebo or escalating doses of QuadraMune™[1]. Elevation of innate immune response activity was observed, together with a decreased responsiveness towards inflammatory stimuli. These preliminary data were analyzed by the Company's Scientific Advisory Board, who then recommended proceeding to the larger trial.
"At Therapeutic Solutions International we believe only in hard science. As a medical doctor who is on the frontlines of the war with Coronavirus, I and my staff take QuadraMune™ daily," said James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "The laboratory and early clinical results seen with QuadraMune™ are truly inspiring. We believe the time has come to jump into a large clinical trial to generate the data necessary to truly convince our colleagues and the world of the potential efficacy of this immune-stimulatory and anti-inflammatory approach."
The clinical trial calls for the daily administration of QuadraMune™ for a period of twelve weeks. Rates of infection will be assessed compared to controls. Subjects eligible to enter the trial are high-risk individuals, which are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.
"If you look historically at pandemics, almost all of them have a Second Wave, which is almost always substantially more devastating than the first. We at Therapeutic Solutions International are pleased to apply our work in the area of inflammation and immune stimulation, to attempt to add another arrow in our quiver against this invisible enemy," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In some ways, Coronavirus is like cancer…you want to increase activation of innate immunity and suppress inflammatory reactions simultaneously. We have been doing this research successfully using NanoStilbene™ in cancer, and now we are transposing our findings into the field of virology."
This one will go to dollars
Bs posts dude
Do better dd....going to multiple dimes in a few days
Ripping to multiple dimes here
Next week will be insane here
10 bagger short time here
a dime today?
stupid post man
i agree Jack ….back to 0,025 within days
dumb and dumber posts here....this is the dumbest
TPTW's upcoming Mobile TV and Social Media platform. It is the intent of TPTW to assist InnovQor in being publicly traded as a vehicle for raising capital. Upon the merger, TPTW will become a minority interest owner in InnovoQor. Individuals can learn more about the Joint Venture in the Company's Form 8k filing on the transaction.
goodbye Jack! you won't be missed here!
you are funny Jack...not….
going higher…..much higher
no one is talking about any buy out news...only you…..
Better slap the ask and enjoy the ride north
Closing great...tomorrow to 3
5's this week?
.....to start the process to move from the OTC markets to achieve a listed company status over the next 3 to 5 quarters…...